These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 30275228)
1. Intraperitoneal and Systemic Chemotherapy for Patients with Gastric Cancer with Peritoneal Metastasis: A Phase II Trial. Shinkai M; Imano M; Chiba Y; Hiraki Y; Kato H; Iwama M; Shiraishi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T Anticancer Res; 2018 Oct; 38(10):5975-5981. PubMed ID: 30275228 [TBL] [Abstract][Full Text] [Related]
2. Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study. Shinkai M; Imano M; Chiba Y; Hiraki Y; Kato H; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T Anticancer Res; 2018 Oct; 38(10):5969-5974. PubMed ID: 30275227 [TBL] [Abstract][Full Text] [Related]
3. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer. Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009 [TBL] [Abstract][Full Text] [Related]
4. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Yamaguchi H; Kitayama J; Ishigami H; Emoto S; Yamashita H; Watanabe T Cancer; 2013 Sep; 119(18):3354-8. PubMed ID: 23798046 [TBL] [Abstract][Full Text] [Related]
5. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407). Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A; Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560 [TBL] [Abstract][Full Text] [Related]
6. Feasibility of weekly intraperitoneal versus intravenous paclitaxel therapy delivered from the day of radical surgery for gastric cancer: a preliminary safety analysis of the INPACT study, a randomized controlled trial. Kodera Y; Takahashi N; Yoshikawa T; Takiguchi N; Fujitani K; Ito Y; Miyamoto K; Takayama O; Imano M; Kobayashi D; Miyashita Y; Morita S; Sakamoto J Gastric Cancer; 2017 Jan; 20(1):190-199. PubMed ID: 26879545 [TBL] [Abstract][Full Text] [Related]
7. Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Ishigami H; Yamaguchi H; Yamashita H; Asakage M; Kitayama J Gastric Cancer; 2017 Mar; 20(Suppl 1):128-134. PubMed ID: 28028665 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination. Fujiwara Y; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Okada K; Mori M; Doki Y Ann Surg Oncol; 2011 Dec; 18(13):3726-31. PubMed ID: 21584835 [TBL] [Abstract][Full Text] [Related]
9. Phase I Study of Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Cisplatin for Gastric Cancer with Peritoneal Metastasis. Kobayashi D; Ishigami H; Kanda M; Tanaka C; Yamaguchi H; Kitayama J; Kodera Y Oncology; 2020; 98(1):48-52. PubMed ID: 31487733 [TBL] [Abstract][Full Text] [Related]
10. Salvage gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Kitayama J; Ishigami H; Yamaguchi H; Yamashita H; Emoto S; Kaisaki S; Watanabe T Ann Surg Oncol; 2014 Feb; 21(2):539-46. PubMed ID: 23975319 [TBL] [Abstract][Full Text] [Related]
11. Pilot study of intraperitoneal administration of paclitaxel and oral S-1 for patients with peritoneal metastasis due to advanced gastric cancer. Tamura S; Miki H; Okada K; Miyake T; Yoshimura M; Suzuki R; Nakahira S; Nakata K; Okamura S; Sugimoto K; Takatsuka Y Int J Clin Oncol; 2008 Dec; 13(6):536-40. PubMed ID: 19093182 [TBL] [Abstract][Full Text] [Related]
12. A phase I study of S-1 in combination with nab-paclitaxel in patients with unresectable or recurrent gastric cancer. Nakayama N; Ishido K; Chin K; Nishimura K; Azuma M; Matsusaka S; Inokuchi Y; Tanabe S; Kumekawa Y; Koizumi W Gastric Cancer; 2017 Mar; 20(2):350-357. PubMed ID: 27189323 [TBL] [Abstract][Full Text] [Related]
13. Phase I study of biweekly intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel for gastric cancer with peritoneal metastasis. Ishigami H; Kitayama J; Kaisaki S; Yamaguchi H; Yamashita H; Emoto S; Nagawa H Oncology; 2010; 79(3-4):269-72. PubMed ID: 21372602 [TBL] [Abstract][Full Text] [Related]
14. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ishigami H; Kitayama J; Kaisaki S; Hidemura A; Kato M; Otani K; Kamei T; Soma D; Miyato H; Yamashita H; Nagawa H Ann Oncol; 2010 Jan; 21(1):67-70. PubMed ID: 19605503 [TBL] [Abstract][Full Text] [Related]
15. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC Trial. Ishigami H; Fujiwara Y; Fukushima R; Nashimoto A; Yabusaki H; Imano M; Imamoto H; Kodera Y; Uenosono Y; Amagai K; Kadowaki S; Miwa H; Yamaguchi H; Yamaguchi T; Miyaji T; Kitayama J J Clin Oncol; 2018 Jul; 36(19):1922-1929. PubMed ID: 29746229 [TBL] [Abstract][Full Text] [Related]
16. Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis. Yamaguchi H; Satoh Y; Ishigami H; Kurihara M; Yatomi Y; Kitayama J Ann Surg Oncol; 2017 Oct; 24(11):3345-3352. PubMed ID: 28726078 [TBL] [Abstract][Full Text] [Related]
17. [Combination Chemotherapy Including Intraperitoneal(IP)Administration of Paclitaxel(PTX)followed by PTX, CDDP and S-1Triplet Chemotherapy for CY1P0 Gastric Cancer]. Shinkai M; Imano M; Hiraki Y; Kato H; Iwama M; Shiraishi O; Yasuda A; Kimura Y; Imamoto H; Furukawa H; Yasuda T Gan To Kagaku Ryoho; 2017 Nov; 44(12):1355-1357. PubMed ID: 29394632 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of single intraperitoneal chemotherapy followed by systemic chemotherapy for gastric cancer with peritoneal metastasis. Imano M; Yasuda A; Itoh T; Satou T; Peng YF; Kato H; Shinkai M; Tsubaki M; Chiba Y; Yasuda T; Imamoto H; Nishida S; Takeyama Y; Okuno K; Furukawa H; Shiozaki H J Gastrointest Surg; 2012 Dec; 16(12):2190-6. PubMed ID: 23099736 [TBL] [Abstract][Full Text] [Related]
19. Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Okabe H; Ueda S; Obama K; Hosogi H; Sakai Y Ann Surg Oncol; 2009 Dec; 16(12):3227-36. PubMed ID: 19777180 [TBL] [Abstract][Full Text] [Related]
20. A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential S-1 plus intravenous paclitaxel for serosa-positive gastric cancer. Peng YF; Imano M; Itoh T; Satoh T; Chiba Y; Imamoto H; Tsubaki M; Nishida S; Yasuda T; Furukawa H J Surg Oncol; 2015 Jun; 111(8):1041-6. PubMed ID: 26060133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]